Published in Am J Transl Res on February 05, 2009
Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee. Cancer Res (2013) 1.66
A systems genetics approach identifies CXCL14, ITGAX, and LPCAT2 as novel aggressive prostate cancer susceptibility genes. PLoS Genet (2014) 1.48
Expression and functional role of orphan receptor GPR158 in prostate cancer growth and progression. PLoS One (2015) 1.41
Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway. Endocr Relat Cancer (2012) 1.14
Prostate cancer and neuroendocrine differentiation: more neuronal, less endocrine? Front Oncol (2015) 1.01
Evaluation of neuroendocrine markers in renal cell carcinoma. Diagn Pathol (2010) 0.99
Interleukin-6: a bone marrow stromal cell paracrine signal that induces neuroendocrine differentiation and modulates autophagy in bone metastatic PCa cells. Autophagy (2012) 0.94
Neuroendocrine differentiation of prostate cancer. Asian J Androl (2013) 0.93
Mouse models of prostate cancer: picking the best model for the question. Cancer Metastasis Rev (2014) 0.93
The Siah2-HIF-FoxA2 axis in prostate cancer – new markers and therapeutic opportunities. Oncotarget (2010) 0.91
Down-regulation of RE-1 silencing transcription factor (REST) in advanced prostate cancer by hypoxia-induced miR-106b~25. Exp Cell Res (2013) 0.86
SRC: marker or actor in prostate cancer aggressiveness. Front Oncol (2014) 0.83
Germline genetic variation modulates tumor progression and metastasis in a mouse model of neuroendocrine prostate carcinoma. PLoS One (2013) 0.83
Nonblocking Monoclonal Antibody Targeting Soluble MIC Revamps Endogenous Innate and Adaptive Antitumor Responses and Eliminates Primary and Metastatic Tumors. Clin Cancer Res (2015) 0.82
Clinicopathological analysis on small cell carcinoma of the prostate in chinese patients. J Cancer (2014) 0.80
Expression of a neuroendocrine gene signature in gastric tumor cells from CEA 424-SV40 large T antigen-transgenic mice depends on SV40 large T antigen. PLoS One (2012) 0.78
Detection and organ-specific ablation of neuroendocrine cells by synaptophysin locus-based BAC cassette in transgenic mice. PLoS One (2013) 0.78
Prostate cancer with Paneth cell-like neuroendocrine differentiation has recognizable histomorphology and harbors AURKA gene amplification. Hum Pathol (2014) 0.78
Molecular aspects of prostate cancer with neuroendocrine differentiation. Chin J Cancer Res (2016) 0.78
The molecular basis for ethnic variation and histological subtype differences in prostate cancer. Sci China Life Sci (2013) 0.77
IL-1β induces p62/SQSTM1 and represses androgen receptor expression in prostate cancer cells. J Cell Biochem (2014) 0.76
Up-Regulated Expression of LAMP2 and Autophagy Activity during Neuroendocrine Differentiation of Prostate Cancer LNCaP Cells. PLoS One (2016) 0.76
Molecular pathology of prostate cancer revealed by next-generation sequencing: opportunities for genome-based personalized therapy. Curr Opin Urol (2013) 0.76
Melatonin, a Full Service Anti-Cancer Agent: Inhibition of Initiation, Progression and Metastasis. Int J Mol Sci (2017) 0.75
Gallium-68 DOTATOC PET/CT in vivo characterization of somatostatin receptor expression in the prostate. Cancer Biother Radiopharm (2014) 0.75
Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles. Oncotarget (2016) 0.75
Reversible lysine-specific demethylase 1 antagonist HCI-2509 inhibits growth and decreases c-MYC in castration- and docetaxel-resistant prostate cancer cells. Prostate Cancer Prostatic Dis (2016) 0.75
De novo large cell neuroendocrine carcinoma of the prostate, case report and literature review. Am J Clin Exp Urol (2014) 0.75
Salmonella Bacterial Monotherapy Reduces Autochthonous Prostate Tumor Burden in the TRAMP Mouse Model. PLoS One (2016) 0.75
Cooperation among heterogeneous prostate cancer cells in the bone metastatic niche. Oncogene (2016) 0.75
Efficacy, quality of life, and safety of cabazitaxel in Canadian metastatic castration-resistant prostate cancer patients treated or not with prior abiraterone. Can Urol Assoc J (2016) 0.75
Somatic Mutation Analyses in Studies of the Clonal Evolution and Diagnostic Targets of Prostate Cancer. Curr Genomics (2017) 0.75
Gene expression correlates of clinical prostate cancer behavior. Cancer Cell (2002) 16.27
Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell (2003) 8.11
Molecular characterization of human prostate carcinoma cell lines. Prostate (2003) 3.81
Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate (2003) 3.44
Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol (2003) 3.17
Androgen receptor is a tumor suppressor and proliferator in prostate cancer. Proc Natl Acad Sci U S A (2008) 2.47
Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model. Prostate (1996) 2.21
Etiology and disease process of benign prostatic hyperplasia. Prostate Suppl (1989) 2.12
Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells. Nature (1998) 2.08
Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res (1999) 1.92
Small cell carcinoma of the prostate: an immunohistochemical study. Am J Surg Pathol (2006) 1.80
Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol (2002) 1.79
Endocrine-paracrine cell types in the prostate and prostatic adenocarcinoma are postmitotic cells. Hum Pathol (1995) 1.73
Etk/Bmx, a tyrosine kinase with a pleckstrin-homology domain, is an effector of phosphatidylinositol 3'-kinase and is involved in interleukin 6-induced neuroendocrine differentiation of prostate cancer cells. Proc Natl Acad Sci U S A (1998) 1.70
Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nat Med (1998) 1.69
Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities. Eur Urol (2005) 1.69
Androgen receptor represses the neuroendocrine transdifferentiation process in prostate cancer cells. Mol Endocrinol (2003) 1.66
Proliferative heterogeneity in the human prostate: evidence for epithelial stem cells. Lab Invest (2000) 1.66
Expression of somatostatin receptor subtypes 2 and 4 in human benign prostatic hyperplasia and prostatic cancer. Prostate (2002) 1.54
Conversion from a paracrine to an autocrine mechanism of androgen-stimulated growth during malignant transformation of prostatic epithelial cells. Cancer Res (2001) 1.54
An allograft model of androgen independent prostatic neuroendocrine carcinoma derived from a large probasin promoter-T antigen transgenic mouse line. J Urol (2004) 1.53
Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK. Oncogene (2004) 1.48
Neuropeptide-induced androgen independence in prostate cancer cells: roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase. Mol Cell Biol (2001) 1.46
Transdifferentiation of prostate cancer cells to a neuroendocrine cell phenotype in vitro and in vivo. J Urol (1999) 1.43
Demonstration of intermediate cells during human prostate epithelial differentiation in situ and in vitro using triple-staining confocal scanning microscopy. Lab Invest (2000) 1.41
STAT3 mediates IL-6-induced neuroendocrine differentiation in prostate cancer cells . Prostate (2000) 1.40
Serum pro-gastrin-releasing peptide (31-98) in benign prostatic hyperplasia and prostatic carcinoma. Urology (2002) 1.40
Bombesin receptor subtypes in human cancers: detection with the universal radioligand (125)I-[D-TYR(6), beta-ALA(11), PHE(13), NLE(14)] bombesin(6-14). Clin Cancer Res (2002) 1.39
Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression. Cancer Res (1999) 1.37
Ionizing radiation induces prostate cancer neuroendocrine differentiation through interplay of CREB and ATF2: implications for disease progression. Cancer Res (2008) 1.33
Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate. Prostate (2009) 1.33
Mouse models of prostate adenocarcinoma with the capacity to monitor spontaneous carcinogenesis by bioluminescence or fluorescence. Cancer Res (2007) 1.33
Immunohistochemical characterization of neuroendocrine cells in prostate cancer. Prostate (2006) 1.32
Ca2+ homeostasis and apoptotic resistance of neuroendocrine-differentiated prostate cancer cells. Cell Death Differ (2004) 1.30
Silibinin decreases prostate-specific antigen with cell growth inhibition via G1 arrest, leading to differentiation of prostate carcinoma cells: implications for prostate cancer intervention. Proc Natl Acad Sci U S A (1999) 1.29
Bombesin stimulates nuclear factor kappa B activation and expression of proangiogenic factors in prostate cancer cells. Cancer Res (2003) 1.27
Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival. Cancer (2002) 1.26
NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice. Cancer Res (2004) 1.24
Association between immunohistochemical expression of vascular endothelial growth factor (VEGF), VEGF-expressing neuroendocrine-differentiated tumor cells, and outcome in prostate cancer patients subjected to watchful waiting. Clin Cancer Res (2000) 1.24
Differential expression of interleukin-8 and its receptors in the neuroendocrine and non-neuroendocrine compartments of prostate cancer. Am J Pathol (2005) 1.22
A human- and male-specific protocadherin that acts through the wnt signaling pathway to induce neuroendocrine transdifferentiation of prostate cancer cells. Cancer Res (2005) 1.22
RNA interference of achaete-scute homolog 1 in mouse prostate neuroendocrine cells reveals its gene targets and DNA binding sites. Proc Natl Acad Sci U S A (2004) 1.22
Multidirectional differentiation in the normal, hyperplastic, and neoplastic human prostate: simultaneous demonstration of cell-specific epithelial markers. Hum Pathol (1994) 1.21
Neuroendocrine differentiation in human prostatic carcinoma. Hum Pathol (1992) 1.19
Neuroendocrine differentiation in prostatic carcinoma during hormonal treatment. Urology (1998) 1.18
Collocation of androgen receptor gene mutations in prostate cancer. Clin Cancer Res (2001) 1.17
The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy. J Urol (1997) 1.16
Expression of G1 cyclins, cyclin-dependent kinases, and cyclin-dependent kinase inhibitors in androgen-induced prostate proliferation in castrated rats. Cell Growth Differ (1996) 1.15
Progression of prostate cancer to neuroendocrine cell tumor. Int J Urol (2001) 1.15
Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype. Clin Cancer Res (2001) 1.13
Aberrant activation of androgen receptor in a new neuropeptide-autocrine model of androgen-insensitive prostate cancer. Cancer Res (2009) 1.13
Prostate stem cells and benign prostatic hyperplasia. Prostate (2008) 1.12
Expression of serotonin receptors and role of serotonin in human prostate cancer tissue and cell lines. Prostate (2004) 1.08
Androgen-driven prostate epithelial cell proliferation and differentiation in vivo involve the regulation of p27. Mol Endocrinol (2001) 1.07
Accelerated in vivo growth of prostate tumors that up-regulate interleukin-6 is associated with reduced retinoblastoma protein expression and activation of the mitogen-activated protein kinase pathway. Am J Pathol (2003) 1.07
BCL-2 proto-oncogene expression in prostate cancer and its relationship to the prostatic neuroendocrine cell. Arch Pathol Lab Med (1994) 1.07
Novel regulation of type IV collagenase (matrix metalloproteinase-9 and -2) activities by transforming growth factor-beta1 in human prostate cancer cell lines. Mol Biol Cell (1999) 1.07
Neuroendocrine cells in benign and malignant prostate tissue: morphogenesis, proliferation, and androgen receptor status. Prostate Suppl (1998) 1.06
Expression of membrane-type 1 matrix metalloproteinase (MT1-MMP) on prostate cancer cell lines. Cancer Lett (2000) 1.05
Bombesin stimulates the motility of human prostate-carcinoma cells through tyrosine phosphorylation of focal adhesion kinase and of integrin-associated proteins. Int J Cancer (1997) 1.04
Overexpression of an alpha 1H (Cav3.2) T-type calcium channel during neuroendocrine differentiation of human prostate cancer cells. J Biol Chem (2002) 1.04
Neuropeptides as autocrine growth factors in cancer cells. Curr Pharm Des (2003) 1.03
Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study. Urology (2005) 1.03
Androgen-independent growth and tumorigenesis of prostate cancer cells are enhanced by the presence of PKA-differentiated neuroendocrine cells. Cancer Res (2007) 1.03
Peptide-hormone- and serotonin-immunoreactive tumour cells in carcinoma of the prostate. Pathol Res Pract (1987) 1.02
Receptor protein tyrosine phosphatase alpha signaling is involved in androgen depletion-induced neuroendocrine differentiation of androgen-sensitive LNCaP human prostate cancer cells. Oncogene (2003) 1.02
Interleukin-6 induces G1 arrest through induction of p27(Kip1), a cyclin-dependent kinase inhibitor, and neuron-like morphology in LNCaP prostate tumor cells. Biochem Biophys Res Commun (1999) 1.02
Activation of the Erk mitogen-activated protein kinase pathway stimulates neuroendocrine differentiation in LNCaP cells independently of cell cycle withdrawal and STAT3 phosphorylation. Cancer Res (2002) 1.02
Regressive changes and neuroendocrine differentiation in prostate cancer after neoadjuvant hormonal treatment. Prostate (2000) 1.00
Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease. Endocr Relat Cancer (2005) 1.00
Relation of endocrine-paracrine cells to cell proliferation in normal, hyperplastic, and neoplastic human prostate. Prostate (1991) 1.00
Apoptosis resistance of neuroendocrine phenotypes in prostatic adenocarcinoma. Prostate (2002) 1.00
Brain metastasis from prostate small cell carcinoma: not to be neglected. Can J Neurol Sci (2002) 0.99
Effects of the calciotrophic peptides calcitonin and parathyroid hormone on prostate cancer growth and chemotaxis. Prostate (1997) 0.98
Involvement of p27Kip1 in G1 arrest by high dose 5 alpha-dihydrotestosterone in LNCaP human prostate cancer cells. Oncogene (2000) 0.97
Morphology and therapeutic strategies for neuroendocrine tumors of the genitourinary tract. Cancer (2002) 0.97
Multipathways for transdifferentiation of human prostate cancer cells into neuroendocrine-like phenotype. Biochim Biophys Acta (2001) 0.97
Neuroendocrine cell differentiation in the CWR22 human prostate cancer xenograft: association with tumor cell proliferation prior to recurrence. Prostate (2004) 0.97
Neuroendocrine cells in human prostate over-express the anti-apoptosis protein survivin. Prostate (2001) 0.97
Neuroendocrine differentiated small cell carcinoma presenting as recurrent prostate cancer after androgen deprivation therapy. BJU Int (2001) 0.97
Inhibition of retinoblastoma protein (Rb) phosphorylation at serine sites and an increase in Rb-E2F complex formation by silibinin in androgen-dependent human prostate carcinoma LNCaP cells: role in prostate cancer prevention. Mol Cancer Ther (2002) 0.97
Vascular endothelial growth factor (VEGF) expression in prostatic tumours and its relationship to neuroendocrine cells. Br J Cancer (1996) 0.97
Interleukin-6 activates phosphatidylinositol-3 kinase, which inhibits apoptosis in human prostate cancer cell lines. Prostate (2000) 0.96
Different profiles of neuroendocrine cell differentiation evolve in the PC-310 human prostate cancer model during long-term androgen deprivation. Prostate (2002) 0.95
Activated 3',5'-cyclic AMP-dependent protein kinase is sufficient to induce neuroendocrine-like differentiation of the LNCaP prostate tumor cell line. J Biol Chem (2000) 0.94
Neurotensin is an autocrine trophic factor stimulated by androgen withdrawal in human prostate cancer. Proc Natl Acad Sci U S A (1994) 0.94
In vitro regulation of pericellular proteolysis in prostatic tumor cells treated with bombesin. Int J Cancer (1998) 0.94
Androgen deprivation of the PC-310 [correction of prohormone convertase-310] human prostate cancer model system induces neuroendocrine differentiation. Cancer Res (2000) 0.94
Gene profiling and pathway analysis of neuroendocrine transdifferentiated prostate cancer cells. Prostate (2009) 0.93
Murine androgen-independent neuroendocrine carcinoma promotes metastasis of human prostate cancer cell line LNCaP. Prostate (2006) 0.93
GRP receptor-mediated immediate early gene expression and transcription factor Elk-1 activation in prostate cancer cells. Regul Pept (2002) 0.93
Neuroendocrine differentiation in prostatic intraepithelial neoplasia and adenocarcinoma. Am J Surg Pathol (1994) 0.92
Neuroendocrine expression in node positive prostate cancer: correlation with systemic progression and patient survival. J Urol (2002) 0.91
Genetic analysis of neuroendocrine tumor cells in prostatic carcinoma. Prostate (2006) 0.90
Pretreatment serum level of neuron specific enolase (NSE) as a prognostic factor in metastatic prostate cancer patients treated with endocrine therapy. Eur Urol (2003) 0.90
Regulation of interleukin-6-mediated PI3K activation and neuroendocrine differentiation by androgen signaling in prostate cancer LNCaP cells. Prostate (2004) 0.90
Primary carcinoid tumor of the prostate with concurrent adenocarcinoma: a case report. Int J Surg Pathol (2004) 0.90
Neutral endopeptidase promotes phorbol ester-induced apoptosis in prostate cancer cells by inhibiting neuropeptide-induced protein kinase C delta degradation. Cancer Res (2000) 0.89
High expression of somatostatin receptors and messenger ribonucleic acid for its receptor subtypes in organ-confined and locally advanced human prostate cancers. J Clin Endocrinol Metab (2000) 0.89
Calcium signaling in prostate cancer cells: evidence for multiple receptors and enhanced sensitivity to bombesin/GRP. Prostate (1997) 0.89
Identification of a cell of origin for human prostate cancer. Science (2010) 6.33
Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell (2011) 4.43
Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance. Nat Med (2010) 3.61
Targeted biopsy in the detection of prostate cancer using an office based magnetic resonance ultrasound fusion device. J Urol (2012) 2.89
Highly efficient capture of circulating tumor cells by using nanostructured silicon substrates with integrated chaotic micromixers. Angew Chem Int Ed Engl (2011) 2.79
The PSA(-/lo) prostate cancer cell population harbors self-renewing long-term tumor-propagating cells that resist castration. Cell Stem Cell (2012) 2.69
Basal epithelial stem cells are efficient targets for prostate cancer initiation. Proc Natl Acad Sci U S A (2010) 2.69
Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. Cancer Res (2012) 2.45
PC3 is a cell line characteristic of prostatic small cell carcinoma. Prostate (2011) 2.13
Clinical application of a 3D ultrasound-guided prostate biopsy system. Urol Oncol (2011) 2.03
Small cell carcinoma of the prostate: an immunohistochemical study. Am J Surg Pathol (2006) 1.80
Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 derived miniRNA as a novel plasma-based biomarker for diagnosing prostate cancer. Eur J Cancer (2013) 1.73
Sex determining region Y-Box 2 (SOX2) is a potential cell-lineage gene highly expressed in the pathogenesis of squamous cell carcinomas of the lung. PLoS One (2010) 1.69
Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee. Cancer Res (2013) 1.66
Long noncoding RNA MALAT-1 is a new potential therapeutic target for castration resistant prostate cancer. J Urol (2013) 1.64
Expression of RNA-binding protein IMP3 (KOC) in benign urothelium and urothelial tumors. Hum Pathol (2008) 1.60
ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin. Mod Pathol (2011) 1.59
Prognostic value and function of KLF4 in prostate cancer: RNAa and vector-mediated overexpression identify KLF4 as an inhibitor of tumor cell growth and migration. Cancer Res (2010) 1.54
Role of autonomous androgen receptor signaling in prostate cancer initiation is dichotomous and depends on the oncogenic signal. Proc Natl Acad Sci U S A (2011) 1.53
CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis. Clin Cancer Res (2010) 1.42
Invasive prostate carcinoma driven by c-Src and androgen receptor synergy. Cancer Res (2010) 1.38
Prostate cancer originating in basal cells progresses to adenocarcinoma propagated by luminal-like cells. Proc Natl Acad Sci U S A (2013) 1.37
Ionizing radiation induces prostate cancer neuroendocrine differentiation through interplay of CREB and ATF2: implications for disease progression. Cancer Res (2008) 1.33
Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression. Proc Natl Acad Sci U S A (2012) 1.32
Purification and direct transformation of epithelial progenitor cells from primary human prostate. Nat Protoc (2011) 1.30
Selective expression of CD44, a putative prostate cancer stem cell marker, in neuroendocrine tumor cells of human prostate cancer. Prostate (2009) 1.26
CD44 expression is a feature of prostatic small cell carcinoma and distinguishes it from its mimickers. Hum Pathol (2008) 1.21
Androgen receptor splice variant AR3 promotes prostate cancer via modulating expression of autocrine/paracrine factors. J Biol Chem (2013) 1.18
Regulated proteolysis of Trop2 drives epithelial hyperplasia and stem cell self-renewal via β-catenin signaling. Genes Dev (2012) 1.17
p75NTR regulates Abeta deposition by increasing Abeta production but inhibiting Abeta aggregation with its extracellular domain. J Neurosci (2011) 1.17
Stromal epigenetic dysregulation is sufficient to initiate mouse prostate cancer via paracrine Wnt signaling. Proc Natl Acad Sci U S A (2012) 1.16
Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway. Endocr Relat Cancer (2012) 1.14
Malakoplakia of the prostate on needle core biopsy: a case report and review of the literature. Int J Surg Pathol (2007) 1.13
Cell-autonomous activation of the PI3-kinase pathway initiates endometrial cancer from adult uterine epithelium. Proc Natl Acad Sci U S A (2010) 1.13
Functional domain and motif analyses of androgen receptor coregulator ARA70 and its differential expression in prostate cancer. J Biol Chem (2004) 1.13
Metastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets. Proc Natl Acad Sci U S A (2013) 1.12
Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway is essential for neuroendocrine differentiation of prostate cancer. J Biol Chem (2006) 1.12
Fibrolamellar carcinoma of the liver exhibits immunohistochemical evidence of both hepatocyte and bile duct differentiation. Mod Pathol (2010) 1.11
A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel. Cancer (2008) 1.10
Stem-like epithelial cells are concentrated in the distal end of the fallopian tube: a site for injury and serous cancer initiation. Stem Cells (2012) 1.09
Androgenic dependence of exophytic tumor growth in a transgenic mouse model of bladder cancer: a role for thrombospondin-1. BMC Urol (2008) 1.08
NanoVelcro Chip for CTC enumeration in prostate cancer patients. Methods (2013) 1.05
Littoral cell angioma of the spleen. AJR Am J Roentgenol (2007) 1.05
Association between tumor-associated macrophage infiltration, high grade prostate cancer, and biochemical recurrence after radical prostatectomy. Am J Cancer Res (2013) 1.04
Expression of p14ARF, p15INK4b, p16INK4a, and DCR2 increases during prostate cancer progression. Mod Pathol (2006) 1.02
Sonographic features of biliary hamartomas with histopathologic correlation. J Ultrasound Med (2006) 1.01
Co-opted JNK/SAPK signaling in Wnt/beta-catenin-induced tumorigenesis. Neoplasia (2008) 1.00
Mucinous tubular and spindle cell carcinoma of the kidney with sarcomatoid differentiation. Int J Clin Exp Pathol (2008) 1.00
Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer? Cancer (2007) 0.97
Schwannoma of the kidney. Mod Pathol (2008) 0.96
Absence of Y chromosome in human placental site trophoblastic tumor. Mod Pathol (2007) 0.94
Overexpression of decoy receptor 3 in precancerous lesions and adenocarcinoma of the esophagus. Am J Clin Pathol (2005) 0.93
Neuroendocrine differentiation of prostate cancer. Asian J Androl (2013) 0.93
Hepatoprotective versus oncogenic functions of STAT3 in liver tumorigenesis. Am J Pathol (2011) 0.91
The expression and function of androgen receptor coactivator p44 and protein arginine methyltransferase 5 in the developing testis and testicular tumors. J Urol (2007) 0.91
Vitamin E succinate inhibits human prostate cancer cell growth via modulating cell cycle regulatory machinery. Biochem Biophys Res Commun (2003) 0.90
The landscape of EGFR pathways and personalized management of non-small-cell lung cancer. Future Oncol (2011) 0.90
Cytoplasmic staining of TTF-1 in the differential diagnosis of hepatocellular carcinoma vs cholangiocarcinoma and metastatic carcinoma of the liver. Am J Clin Pathol (2006) 0.90
Frequent TMPRSS2-ERG rearrangement in prostatic small cell carcinoma detected by fluorescence in situ hybridization: the superiority of fluorescence in situ hybridization over ERG immunohistochemistry. Hum Pathol (2013) 0.90
A new prostate cancer therapeutic approach: combination of androgen ablation with COX-2 inhibitor. Int J Cancer (2008) 0.89
Tyrosine kinase ETK/BMX is up-regulated in bladder cancer and predicts poor prognosis in patients with cystectomy. PLoS One (2011) 0.89
Loss of EGFR signaling regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance. Oncotarget (2014) 0.88
Protein tyrosine phosphatase PTP1B is involved in neuroendocrine differentiation of prostate cancer. Prostate (2006) 0.88
Combination of Rad001 (everolimus) and propachlor synergistically induces apoptosis through enhanced autophagy in prostate cancer cells. Mol Cancer Ther (2012) 0.88
Overexpression of human carcinoma-associated antigen in esophageal adenocarcinoma and its precursor lesions. Am J Clin Pathol (2004) 0.87
Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cells. Cancer Res (2002) 0.87
Endometrial thickness affects the outcome of in vitro fertilization and embryo transfer in normal responders after GnRH antagonist administration. Reprod Biol Endocrinol (2014) 0.86
Hyperactivated JNK is a therapeutic target in pVHL-deficient renal cell carcinoma. Cancer Res (2013) 0.85
Renal oncocytosis presenting in childhood: a case report. Int J Surg Pathol (2003) 0.85
Targeted prostate biopsy: value of multiparametric magnetic resonance imaging in detection of localized cancer. Asian J Androl (2014) 0.85
Intramuscular delivery of a single chain antibody gene prevents brain Aβ deposition and cognitive impairment in a mouse model of Alzheimer's disease. Brain Behav Immun (2010) 0.85
Early detection and measurement of urothelial tumors in mice. Urology (2006) 0.85
Radical prostatectomy: value of prostate MRI in surgical planning. Abdom Imaging (2012) 0.85
Expression of RON Proto-oncogene in Renal Oncocytoma and Chromophobe Renal Cell Carcinoma. Am J Surg Pathol (2004) 0.85
Overexpression of human carcinoma-associated antigen in urothelial carcinoma of the bladder. Arch Pathol Lab Med (2004) 0.84
The influence of percutaneous nephrolithotomy on human systemic stress response, SIRS and renal function. Urol Res (2010) 0.83
Frequent expression of human carcinoma-associated antigen, a mucin-type glycoprotein, in cells of prostatic carcinoma. Arch Pathol Lab Med (2004) 0.82
Epithelial membrane protein 2 is a prognostic indictor for patients with urothelial carcinoma of the upper urinary tract. Am J Pathol (2013) 0.80
Neurosteroid transport by the organic solute transporter OSTα-OSTβ. J Neurochem (2010) 0.80
Arsenic trioxide synergizes with everolimus (Rad001) to induce cytotoxicity of ovarian cancer cells through increased autophagy and apoptosis. Endocr Relat Cancer (2012) 0.80
A novel in vitro assay of tumor-initiating cells in xenograft prostate tumors. Prostate (2010) 0.80
The relationship between polymorphisms at 17 gene sites and hypertension among the Aboriginal Tibetan people. Biomed Environ Sci (2012) 0.79
Overexpression of SKI oncoprotein leads to p53 degradation through regulation of MDM2 protein sumoylation. J Biol Chem (2012) 0.79
Massive Atrial Septal Lipomatous Hypertrophy. Echocardiography (1999) 0.78
Elevated circulating tissue inhibitor of metalloproteinase 1 (TIMP-1) levels are associated with neuroendocrine differentiation in castration resistant prostate cancer. Prostate (2015) 0.78
Thrombin expression in prostate: a novel finding. Cancer Invest (2011) 0.78
SYT-SSX1 (synovial sarcoma translocated) regulates PIASy ligase activity to cause overexpression of NCOA3 protein. J Biol Chem (2011) 0.77
[Relationship between cholecystokinin gene -45C/T polymorphism and schizophrenia and its application in forensic medicine]. Fa Yi Xue Za Zhi (2011) 0.77
High-grade neuroendocrine carcinomas of the lung highly express enhancer of zeste homolog 2, but carcinoids do not. Hum Pathol (2011) 0.77
Expression of claudin-7 in benign kidney and kidney tumors. Int J Clin Exp Pathol (2008) 0.77
The molecular basis for ethnic variation and histological subtype differences in prostate cancer. Sci China Life Sci (2013) 0.77
Molecular pathology of prostate cancer revealed by next-generation sequencing: opportunities for genome-based personalized therapy. Curr Opin Urol (2013) 0.76
Erk/MAP kinase signaling pathway and neuroendocrine differentiation of non-small-cell lung cancer. J Thorac Oncol (2014) 0.76